company background image
STSA

Satsuma Pharmaceuticals NasdaqGM:STSA Stock Report

Last Price

US$0.89

Market Cap

US$29.6m

7D

24.5%

1Y

-81.7%

Updated

28 Nov, 2022

Data

Company Financials +
STSA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

STSA Stock Overview

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines.

Satsuma Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Satsuma Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.89
52 Week HighUS$8.08
52 Week LowUS$0.59
Beta0.42
1 Month Change-82.34%
3 Month Change-85.86%
1 Year Change-81.73%
3 Year Change-93.77%
5 Year Changen/a
Change since IPO-94.71%

Recent News & Updates

Recent updates

Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?

Sep 02
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?

Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation

May 13
Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation

Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?

Jan 26
Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?

Shareholder Returns

STSAUS PharmaceuticalsUS Market
7D24.5%1.5%0.3%
1Y-81.7%12.2%-20.5%

Return vs Industry: STSA underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: STSA underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is STSA's price volatile compared to industry and market?
STSA volatility
STSA Average Weekly Movement26.2%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: STSA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.

Volatility Over Time: STSA's weekly volatility has increased from 16% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201625John Kollinshttps://www.satsumarx.com

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company’s lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Satsuma Pharmaceuticals, Inc. Fundamentals Summary

How do Satsuma Pharmaceuticals's earnings and revenue compare to its market cap?
STSA fundamental statistics
Market CapUS$29.60m
Earnings (TTM)-US$62.48m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STSA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$62.48m
Earnings-US$62.48m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.89
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did STSA perform over the long term?

See historical performance and comparison